在线观看免费aaa高清完整版_中文字幕在线永久在线视频西瓜_亚洲精品播放视频_久久大学生精品视频_亚洲国产欧美在线人成大黄瓜_国产一级a?在线观看_精品国产日韩一区二区三区_做暖暖视频在线观看_欧美日韩高清视视频在线观看_久久人人爽精品玩人妻aⅤ,厕所露脸高清近距离偷.,我与漂亮的女教师们,欧美午夜精品一区二区蜜桃

當(dāng)前位置:網(wǎng)站首頁 > 學(xué)術(shù)論文 > > 2023 ASCO前瞻 | 泌尿腫瘤領(lǐng)域重磅研究及中國研究一覽

2023 ASCO前瞻 | 泌尿腫瘤領(lǐng)域重磅研究及中國研究一覽

文章來源:武漢配發(fā)器械網(wǎng)瀏覽次數(shù):1995
核心提示:一年一度的全球腫瘤界盛會(huì)-美國臨床腫瘤學(xué)會(huì)(ASCO)年會(huì)將于當(dāng)?shù)貢r(shí)間6月2日-6月6日召開,。ASCO年會(huì)是世界上規(guī)模大、學(xué)術(shù)水平高、具權(quán)威的臨床腫瘤學(xué)會(huì)議,,致力于癌癥的預(yù)防、治療和改善患者管理,以展


一年一度的全球腫瘤界盛會(huì)-美國臨床腫瘤學(xué)會(huì)(ASCO)年會(huì)將于當(dāng)?shù)貢r(shí)間6月2日-6月6日召開。ASCO年會(huì)是世界上規(guī)模大,、學(xué)術(shù)水平高、具權(quán)威的臨床腫瘤學(xué)會(huì)議,,致力于癌癥的預(yù)防,、治療和改善患者管理,以展示腫瘤的基礎(chǔ)研究和臨床新研究為特點(diǎn),,討論當(dāng)前國際先進(jìn)的治療方法,。醫(yī)脈通精選了泌尿腫瘤領(lǐng)域Oral Abstract Session部分的13項(xiàng)重磅研究及Poster Session部分入選的8項(xiàng)中國研究,小編帶您先睹為快,。

 

口頭報(bào)告專場(Oral Abstract Session

前列腺/睪丸/陰莖腫瘤

 

摘要號:LBA5000

標(biāo)題:Prostate irradiation in men with de novo, low-volume, me[x]tastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design.

報(bào)告人:Alberto Bossi

 

摘要號:5004

標(biāo)題:TALAPRO-2: Phase 3 study of talazoparib (TALA) enzalutamide (ENZA) versus placebo (PBO) ENZA as first-line (1L) treatment for patients (pts) with me[x]tastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.

報(bào)告人:Karim Fizazi

 

摘要號:5005

標(biāo)題:LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with me[x]tastatic castration resistant prostate cancer (mCRPC).

報(bào)告人:Shahneen Sandhu

 

口頭報(bào)告專場(Oral Abstract Session

LBA4619的演示及討論

 

摘要號:LBA4619

標(biāo)題:Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or me[x]tastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt).

報(bào)告人:Yohann Loriot

 

口頭報(bào)告專場(Oral Abstract Session

腎臟/膀胱腫瘤

 

摘要號:LBA4500

標(biāo)題:Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in me[x]tastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study.

報(bào)告人:Toni K. Choueiri

 

摘要號:LBA4501

標(biāo)題:Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.

報(bào)告人:Brian I. Rini

 

摘要號:4502

標(biāo)題:Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).

報(bào)告人:Thomas E. Hutson

 

摘要號:4503

標(biāo)題:Overall survival (OS) by response to first-line (1L) induction treatment with atezolizumab (atezo) platinum/gemcitabine (plt/gem) vs placebo plt/gem in patients (pts) with me[x]tastatic urothelial carcinoma (mUC): Updated data from the IMvigor130 OS final analysis.

報(bào)告人:Enrique Grande

 

摘要號:4504

標(biāo)題:Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA CET) for patients (pts) with me[x]tastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse study.

報(bào)告人:Arlene O. Siefker-Radtke

 

摘要號:4505

標(biāo)題:Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or me[x]tastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up.

報(bào)告人:Shilpa Gupta

 

摘要號:4506

標(biāo)題:Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial.

報(bào)告人:Robert J. Motzer

 

摘要號:LBA4507

標(biāo)題:Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial.

報(bào)告人:Christian Pfister

 

摘要號:LBA4508

標(biāo)題:SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer.

報(bào)告人:Seth P. Lerner

 

壁報(bào)專場(Poster Session

前列腺/睪丸/陰莖腫瘤

 

摘要號:5057

海報(bào)號:151

標(biāo)題:Tumor heterogeneity and treatment response assessment using next generation imaging and liquid biopsy in patients with me[x]tastatic castration resistant prostate cancer receiving abiraterone (ANGELA): A single-center prospective observational trial.

報(bào)告人:朱耀,,復(fù)旦大學(xué)附屬腫瘤醫(yī)院

 

摘要號:5065

海報(bào)號:159

標(biāo)題:Deutenzalutamide, an oral deuterated androgen receptor inhibitor, vs placebo for patients with mCRPC who have experienced treatment failure with abiraterone and docetaxel: Results of the HC-1119-04 phase 3 trial.

報(bào)告人:葉定偉,復(fù)旦大學(xué)附屬腫瘤醫(yī)院

 

壁報(bào)專場(Poster Session

腎臟/膀胱腫瘤

 

摘要號:4521

海報(bào)號:13

標(biāo)題:Effect of KDR mutations on efficacy of immune checkpoint inhibitors in patients with bladder cancer.

報(bào)告人:戴洪海,,山東省立醫(yī)院

 

摘要號:4533

海報(bào)號:25

標(biāo)題:Preliminary results from a phase II study comparing sunitinib alone or with stereotactic body radiotherapy (SBRT) for newly diagnosed oligome[x]tastatic renal cell carcinoma.

報(bào)告人:劉洋,,中山大學(xué)腫瘤防治中心

 

摘要號:4543

海報(bào)號:35

標(biāo)題:Immunoglobulin as a predictive biomarker for the efficacy of immune checkpoint inhibitor combined with VEGF-TKI in me[x]tastatic renal cell carcinoma.

報(bào)告人:Honglei Cui,,中國醫(yī)學(xué)科學(xué)院腫瘤醫(yī)院

 

摘要號:4566

海報(bào)號:58

標(biāo)題:Disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate (ADC), combined with toripalimab in patients with locally advanced or me[x]tastatic urothelial carcinoma: An open-label phase 1b/2 study.

報(bào)告人:盛錫楠,北京大學(xué)腫瘤醫(yī)院

 

摘要號:4585

海報(bào)號:77

標(biāo)題:Final analysis results from a multicenter clinical study of tislelizumab combined with gemcitabine and cisplatin as neoadjuvant therapy in patients with cT2-T4aN0M0 MIBC.

報(bào)告人:林天歆,,中山大學(xué)孫逸仙紀(jì)念醫(yī)院

 

-->

政策法規(guī)更多 >>

三部門發(fā)文:不能變相取消縣級中醫(yī)醫(yī)院,,應(yīng)提升其電子病歷應(yīng)用能力

三部門發(fā)文:不能變相取消縣級中醫(yī)醫(yī)院,,應(yīng)提升其電子病歷應(yīng)用能力

三部門發(fā)文,,明確不能變相取消縣級中醫(yī)醫(yī)院,還要提...

今年打擊騙保專項(xiàng)整治工作啟動(dòng)
《健康醫(yī)療數(shù)據(jù)合規(guī)流通標(biāo)準(zhǔn)》正式發(fā)布,!
國家衛(wèi)生健康委要求—— 推進(jìn)加速康復(fù)外科診療模式應(yīng)用
山西弘揚(yáng)愛國衛(wèi)生新風(fēng)尚
國家衛(wèi)生健康委等14部門聯(lián)合發(fā)文要求—— 重點(diǎn)整治醫(yī)藥領(lǐng)域突出腐敗問題
DRG付費(fèi)與耗材帶量采購聯(lián)動(dòng)實(shí)施
《老年人疫苗接種科普手冊》發(fā)布
安徽省衛(wèi)健委印發(fā)《2023年隨機(jī)監(jiān)督抽查實(shí)施方案》

新品動(dòng)態(tài)更多 >>

事關(guān)癌癥檢測與治療!我國科研人員有新成果

事關(guān)癌癥檢測與治療,!我國科研人員有新成果

核心提示:GQDNT是一種模塊化自組裝納米粒子,...

新型CRISPR/Cas9 mRNA脂質(zhì)納米顆粒治療乙型肝炎
新研究發(fā)現(xiàn)不依賴于細(xì)菌感染即可修復(fù)傷口的機(jī)制!
重大進(jìn)展!新研究發(fā)現(xiàn)不依賴于細(xì)菌感染即可修復(fù)傷口的機(jī)制,!
造血干細(xì)胞體外擴(kuò)增有新策略
聚焦微生物組生態(tài)系統(tǒng)療法(MET)開發(fā)
新型凝膠可完全治侵襲性腦腫瘤
Sotorasib治療KRAS p.G12C基因突變胰腺癌新進(jìn)展
慢性偏頭痛新藥獲FDA批準(zhǔn)!慢性偏頭痛患者福音

熱門關(guān)鍵詞

床頭柜 麻醉車 護(hù)理車

熱門產(chǎn)品